Novo Nordisk A/S (NEO:NVON)
Canada flag Canada · Delayed Price · Currency is CAD
5.14
+0.06 (1.18%)
At close: Nov 28, 2025

Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of CAD 305.53 billion. The enterprise value is 320.42 billion.

Market Cap305.53B
Enterprise Value 320.42B

Important Dates

The last earnings date was Wednesday, November 5, 2025.

Earnings Date Nov 5, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) -0.46%
Shares Change (QoQ) +0.00%
Owned by Insiders (%) 0.02%
Owned by Institutions (%) 29.81%
Float 3.19B

Valuation Ratios

The trailing PE ratio is 13.46 and the forward PE ratio is 12.81.

PE Ratio 13.46
Forward PE 12.81
PS Ratio 4.42
PB Ratio 8.22
P/TBV Ratio 22.05
P/FCF Ratio 21.16
P/OCF Ratio 11.28
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.85, with an EV/FCF ratio of 22.20.

EV / Earnings 14.11
EV / Sales 4.68
EV / EBITDA 8.85
EV / EBIT 9.61
EV / FCF 22.20

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.60.

Current Ratio 0.78
Quick Ratio 0.53
Debt / Equity 0.60
Debt / EBITDA 0.61
Debt / FCF 1.53
Interest Coverage 19.21

Financial Efficiency

Return on equity (ROE) is 71.46% and return on invested capital (ROIC) is 42.81%.

Return on Equity (ROE) 71.46%
Return on Assets (ROA) 21.11%
Return on Invested Capital (ROIC) 42.81%
Return on Capital Employed (ROCE) 55.29%
Revenue Per Employee 879,141
Profits Per Employee 289,069
Employee Count77,349
Asset Turnover 0.69
Inventory Turnover 1.22

Taxes

In the past 12 months, Novo Nordisk has paid 6.16 billion in taxes.

Income Tax 6.16B
Effective Tax Rate 21.33%

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 5.58
200-Day Moving Average n/a
Relative Strength Index (RSI) 46.73
Average Volume (20 Days) 144,281

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of CAD 69.06 billion and earned 22.71 billion in profits. Earnings per share was 5.11.

Revenue69.06B
Gross Profit 57.62B
Operating Income 33.62B
Pretax Income 28.86B
Net Income 22.71B
EBITDA 36.21B
EBIT 33.62B
Earnings Per Share (EPS) 5.11
Full Income Statement

Balance Sheet

The company has 7.13 billion in cash and 22.15 billion in debt, giving a net cash position of -15.02 billion.

Cash & Cash Equivalents 7.13B
Total Debt 22.15B
Net Cash -15.02B
Net Cash Per Share n/a
Equity (Book Value) 37.18B
Book Value Per Share 8.37
Working Capital -11.48B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 27.09 billion and capital expenditures -12.65 billion, giving a free cash flow of 14.44 billion.

Operating Cash Flow 27.09B
Capital Expenditures -12.65B
Free Cash Flow 14.44B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 83.44%, with operating and profit margins of 48.69% and 32.88%.

Gross Margin 83.44%
Operating Margin 48.69%
Pretax Margin 41.80%
Profit Margin 32.88%
EBITDA Margin 52.44%
EBIT Margin 48.69%
FCF Margin 20.90%

Dividends & Yields

Novo Nordisk does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio 49.88%
Buyback Yield 0.46%
Shareholder Yield 0.46%
Earnings Yield 7.43%
FCF Yield 4.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Novo Nordisk has an Altman Z-Score of 6.16 and a Piotroski F-Score of 4.

Altman Z-Score 6.16
Piotroski F-Score 4